Design, synthesis and evaluation of bicyclic benzamides as novel 5-HT 1F receptor agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 24, 2004, Pages 6011-6016

  Zhang, Deyi ^a   Kohlman, Dan ^a   Krushinski, Joseph ^a   Liang, Sidney ^a   Ying, Bai Ping ^a   Reilly, John E ^b   Dinn, Sean R ^b   Wainscott, David B ^a   Nutter, Suzanne ^a   Gough, Wendy ^a   Nelson, David L G ^a   Schaus, John M ^a   Xu, Yao Chang ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Albany Molecular Research   (United States)

Author keywords

5 HT 1F receptor agonist; Migraine

Indexed keywords

BENZAMIDE DERIVATIVE; INDAZOLE DERIVATIVE; INDOLE DERIVATIVE; INDOLINE; ISOXAZOLE DERIVATIVE; SEROTONIN 1 AGONIST; SEROTONIN 1F RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; GEOMETRY; HYBRIDIZATION;

BENZAMIDES; BICYCLO COMPOUNDS, HETEROCYCLIC; BINDING, COMPETITIVE; EVALUATION STUDIES; MOLECULAR STRUCTURE; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 8844286178     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.09.079     Document Type: Article

References (35)

1. R.W. Fuller Adv. Drug Res. 17 1988 349
2. D. Hoyer, D.E. Clarke, J.R. Fozard, P.R. Hartig, G.R. Martin, E.J. Mylecharane, P.R. Saxena, and P.P.A. Humphrey Pharmacol. Rev. 46 1994 157
3. D. Hoyer, J.P. Hannon, and G.R. Martin Pharmacol. Biochem. Behav. 71 2002 533
4. M. Hamon, L. Lanfumey, S. El Mestikawy, C. Boni, M.-C. Miquel, F. Bolaños, L. Schechter, and H. Gozlan Neuropsychopharmacology 3 1990 349 and references cited therein
5. L. Lanfumey, and M. Hamon Curr. Drug Targets-CNS Neurol. Disorders 3 2004 1
6. N. Adham, H.-T. Kao, L.E. Schechter, J. Bard, M. Olsen, D. Urquhart, M. Durkin, P.R. Hartig, R.L. Weinshank, and T.A. Branchek Proc. Natl. Acad. Sci. U.S.A. 90 1993 408
7. N. Adham, L.A. Borden, L.E. Schechter, E.L. Gustafson, T.L. Cochran, P.J. Vaysse, R.L. Weinshank, and T.A. Branchek N-S Arch. Pharmacol. 348 1993 566
8. K.W. Johnson, J.M. Schaus, M.M. Durkin, J.E. Audia, S.W. Kaldor, M.E. Flaugh, N. Adham, J.M. Zgombick, M.L. Cohen, T.A. Branchek, and L.A. Phebus NeuroReport 8 1997 2237
9. A.J. Kaumann, M. Frenken, H. Posival, and A.M. Brown Circulation 90 1994 1141
10. D.S. Dupuis, C. Colpaert, and P.J. Pauwels Br. J. Pharmacol. 124 1998 283
11. Overshiner, C. D.; Adham, N.; Zgombick, J. M.; Branchek, T. A.; Calligaro, D. O.; Phebus, L. A.; Roush, M. E.; Johnson, K. W.; Hemrick-Luecke, S. K.; Fuller, R. W.; Lucaites, V. L.; Wainscott, D. B.; Nelson, D. L.; Wikffm, M. C.; Benvenga, M. J.; Audia, J. E.; Schaus, J. M.; Krushinski, J. H.; Kaldor, S. W.; Dressman, B. A.; Leander, J. D. Poster 52,812 presented at the 26th Annual Meeting, Society for Neuroscience, Washington, DC, November, 1996
12. S. Shepheard, L. Edvinsson, M. Cumberbatch, D. Williamson, G. Mason, J. Webb, S. Boyce, and R. Hill Cephalalgia 19 1999 851
13. D.J. Goldstein, K.I. Roon, W.W. Offen, L.A. Phebus, K.W. Johnson, J.M. Schaus, T. VanLaar, and M.D. Ferrari Celphalalgia 19 1999 318
14. D.J. Goldstein, K.I. Roon, W.W. Offen, N.M. Ramadan, L.A. Phebus, K.W. Johnson, J.M. Schaus, and M.D. Ferrari Lancet 358 2001 1230
15. M.L. Cohen, and K.W. Schenck JPET 290 1999 935
16. M.L. Cohen, K.W. Johnson, K.W. Schenck, and L.A. Phebus Cephalalgia 17 1997 631
17. S.A. Filla, B.M. Mathes, K.W. Johnson, L.A. Phebus, M.L. Cohen, D.L. Nelson, J.M. Zgombick, J.A. Erickson, K.W. Schenck, D.B. Wainscott, T.A. Branchek, and J.M. Schaus J. Med. Chem. 46 2003 3060
18. B.M. Mathes, K.J. Hudziak, J.M. Schaus, Y.-C. Xu, D.L. Nelson, D.B. Wainscott, S.E. Nutter, W.H. Gough, T.A. Branchek, J.M. Zgombick, and S.A. Filla Bioorg. Med. Chem. Lett. 14 2004 167
19. F.J. Brown, Y.K. Yee, L.A. Cronk, K.C. Hebbel, R.D. Krell, and D.W. Snyder J. Med. Chem. 33 1990 1771
20. M. Amir, N. Dhar, and S.K. Tiwari Indian J. Chem. 36B 1997 96
21. A. Breteche, M. Duflos, A. Dassonville, M.-R. Nourrisson, J. Brelet, G. Le Baut, N. Grimaud, and J.-Y. Petit J. Enzym. Inhib. Med. Chem. 17 2002 415
22. P. Fludzinski, D.A. Evrard, W.E. Bloomquist, W.B. Lacefield, W. Pfeifer, N.D. Jones, J.B. Deeter, and M.L. Cohen J. Med. Chem. 30 1987 1535
23. M. Pigini, M. Giannella, F. Gualtieri, and C. Melchiorre Eur. J. Med. Chem. 10 1975 29
24. M. Pigini, M. Giannella, F. Gualtieri, and C. Melchiorre Eur. J. Med. Chem. 10 1975 33
25. V.G. Matassa, T.P. Maduskuie Jr., H.S. Shapiro, B. Hesp, D.W. Snyder, D. Aharony, R.D. Krell, and R.A. Keith J. Med. Chem. 33 1990 1781
26. The enantiopurity of the resolved product 3A and 3B was determined with chiral HPLC (ChiralpakAD, 0.46 × 25 cm, 1.0 mL/min, 40% isopropanol and 60% heptane with 0.2% dimethylethylamine): 3A: 95% ee; 3B: 75% ee
27. N.J. Bach, E.C. Kornfeld, J.A. Clemens, E.B. Smalstig, and C.A. Frederickson J. Med. Chem. 23 1980 492
28. K. Sasakura, A. Kawasaki, and T. Sugasawa Synth. Commun. 18 1988 259
29. A.J. Bridges, A. Lee, E.C. Maduakor, and C.E. Schwartz Tetrahedron Lett. 33 1992 7495
30. J.P. Wolfe, J. Åhman, J. Sadighi, R.A. Singer, and S.L. Buchwald Tetrahedron Lett. 38 1997 6367
31. B.G. Szczepankiewicz, and C.H. Heathcock Tetrahedron 53 1997 8853
32. R.L. Weinshank, J.M. Zgombick, M.J. Macchi, T.A. Branchek, and P.R. Hartig Proc. Natl. Acad. Sci. U.S.A. 89 1992 3630
33. J.M. Zgombick, R.L. Weinshank, M. Macchi, L.E. Schechter, T.A. Branchek, and P.R. Hartig Mol. Pharmacol. 40 1991 1036
34. D.B. Wainscott, K.W. Johnson, L.A. Phebus, J.M. Schaus, and D.L. Nelson Eur. J. Pharmacol. 352 1998 117
35. K. Rasmussen, D.O. Calligaro, J.F. Czachura, L.J. Dreshfield-Ahmad, D.C. Evans, S.K. Hemrick-Luecke, M.J. Kallman, W.T. Kendrick, J.D. Leander, D.L. Nelson, C.D. Overshiner, D.B. Wainscott, M.C. Wolff, D.T. Wong, T.A. Branchek, J.M. Zgombick, and Y.-C. Yu J. Pharmacol. Exp. Ther. 294 2000 688